ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, announced they have signed a non-exclusive agreement granting access to ERS' foundational CRISPR/Cas9 patent portfolio.

The license agreement enhances Dyadic's ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms.  

John E. Milad, CEO, ERS Genomics, said: "Dyadic's work illustrates how broad access to foundational CRISPR/Cas9 technology can drive efficiencies across life sciences and bio-industrial sectors. This agreement reflects our commitment to enabling responsible and equitable use of CRISPR/Cas9, ensuring that organisations across the sector can apply this Nobel Prize-winning technology with confidence."

Joe Hazelton, President and COO, Dyadic Applied BioSolutions, commented: "Access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic's proprietary C1 and Dapibus production platforms.

"This agreement supports both Dyadic's internal product pipeline and the customized production strains we develop for our partners. By integrating CRISPR-based gene editing into our development workflow, we can boost strain performance, efficiency, and adaptability, delivering greater value across the life sciences, food and nutrition, and bio-industrial sectors."

Financial details of the agreement were not disclosed.